{"id":1203,"date":"2023-12-28T14:40:53","date_gmt":"2023-12-28T14:40:53","guid":{"rendered":"https:\/\/journal.nncf.kz\/?p=1203"},"modified":"2024-04-18T12:33:32","modified_gmt":"2024-04-18T12:33:32","slug":"literature-review-protease-inhibitors-as-promising-agents-in-the-fight-against-covid-19-evaluation-of-antiviral-activity","status":"publish","type":"post","link":"https:\/\/journal.nncf.kz\/en\/literature-review-protease-inhibitors-as-promising-agents-in-the-fight-against-covid-19-evaluation-of-antiviral-activity\/","title":{"rendered":"LITERATURE REVIEW: PROTEASE INHIBITORS AS PROMISING AGENTS IN THE FIGHT AGAINST COVID-19 \u2013 EVALUATION OF ANTIVIRAL ACTIVITY"},"content":{"rendered":"

Received: November 15, 2023\/ Accepted: November 17, 2023\/ Published online: December 28, 2023
\n\u0423\u0414\u041a 615.035.1
\nDOI: 10.26212\/2227-1937.2023.19.64.019<\/a><\/p>\n

I.R. Fakhradiyev, ORCID: http:\/\/orcid:0000-0003-0528-3874
\nT.M. Saliev, ORCID: http:\/\/orcid:0000-0001-5696-6363
\nSh.B. Tanabayeva, ORCID: http:\/\/orcid:0000-0003-1826-0460
\nT.R. Fazylov, ORCID: http:\/\/orcid:0000-0001-9604-5155
\nM.B. Kulimbet, ORCID: http:\/\/orcid:0000-0003-4399-700X
\nK.A. Muratova, ORCID: http:\/\/orcid:0009-0001-7011-9213
\nN.S. Ahmad, ORCID: http:\/\/orcid:0000-0002-7180-2006
\nK.B. Abdykerimova, ORCID: http:\/\/orcid:0009-0007-6384-0241
\nA.M. Orazymbetova, ORCID: http:\/\/orcid:0009-0002-0187-4220
\nS.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan<\/p>\n

LITERATURE REVIEW: PROTEASE INHIBITORS AS PROMISING AGENTS IN THE FIGHT AGAINST COVID-19 \u2013 EVALUATION OF ANTIVIRAL ACTIVITY<\/p>\n

Resume:
\nBackground: The COVID-19 pandemic has necessitated an urgent search for effective therapeutics. Protease inhibitors have
\ngained considerable attention as potential antiviral agents against SARS-CoV-2. This literature review aims to evaluate the
\ncurrent state of research on the antiviral activity of protease inhibitors against SARS-CoV-2, focusing on their mechanism of
\naction, in-vitro efficacy, clinical trial findings, and issues related to drug resistance and side effects.
\nMethods: A comprehensive search was conducted across multiple databases, including PubMed, Scopus, and Google Scholar,
\nusing relevant keywords. A total of 22 studies, comprising various research designs, were included in the review.
\nResults: Protease inhibitors effectively target key viral enzymes, demonstrating strong binding affinities. In-vitro studies
\ngenerally indicate a broad-spectrum efficacy against SARS-CoV-2. However, clinical trials have shown mixed results, with
\nsome studies indicating significant benefits, while others do not. Side effects are common but generally manageable. The
\nlikelihood of drug resistance remains relatively low but is a potential concern.
\nConclusion: Protease inhibitors hold promise as antiviral agents against SARS-CoV-2 due to their robust mechanisms of
\naction and in-vitro efficacy. However, clinical utility remains a matter of ongoing debate. Further research, particularly longterm and multi-center trials, are essential to fully establish the role of protease inhibitors in COVID-19 treatment. Issues
\nrelated to drug resistance and side effects need to be carefully considered. Overall, protease inhibitors could serve as a
\nvaluable component of a multi-pronged therapeutic approach against COVID-19.
\nKeywords: COVID-19, SARS-CoV-2, Protease Inhibitors, Antiviral Activity, Clinical Trials, Drug Resistance.<\/p>\n

REFERENCES
\n1 Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson
\nNE, Mayer DA, et al. Real-world use of nirmatrelvir\u2013
\nritonavir in outpatients with COVID-19 during the era of
\nomicron variants including BA.4 and BA.5 in Colorado,
\nUSA: a retrospective cohort study. Lancet Infect Dis
\n[Internet]. 2023;23(6):696\u2013705. Available from:
\nhttp:\/\/dx.doi.org\/10.1016\/s1473-3099(23)00011-7
\n2 Alves VM, Bobrowski T, Melo-Filho CC, Korn D,
\nAuerbach S, Schmitt C, et al. QSAR modeling of SARS\u2011CoV
\nMpro inhibitors identifies sufugolix, cenicriviroc,
\nproglumetacin, and other drugs as candidates for
\nrepurposing against SARS\u2011CoV\u20112. Mol Inform [Internet].
\n2021;40(1). Available from:
\nhttp:\/\/dx.doi.org\/10.1002\/minf.202000113
\n3 Brown L-AK, Freemantle N, Breuer J, Dehbi H-M,
\nChowdhury K, Jones G, et al. Early antiviral treatment in
\noutpatients with COVID-19 (FLARE): a structured
\nsummary of a study protocol for a randomised controlled
\ntrial. Trials [Internet]. 2021;22(1). Available from:
\nhttp:\/\/dx.doi.org\/10.1186\/s13063-021-05139-2
\n4 Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, et al. VV116
\nversus nirmatrelvir\u2013ritonavir for oral treatment of covid19. N Engl J Med [Internet]. 2023;388(5):406\u201317.
\nAvailable from:
\nhttp:\/\/dx.doi.org\/10.1056\/nejmoa2208822
\n5 Caso JM, Fern\u00e1ndez-Ruiz M, L\u00f3pez-Medrano F, CaroTeller JM, Lizasoain M, San-Juan R, et al.
\nNirmatrelvir\/ritonavir for the treatment of
\nimmunocompromised adult patients with early\u2011stage
\nsymptomatic COVID\u201119: A real\u2011life experience. J Med Virol
\n[Internet]. 2023;95(9). Available from:
\nhttp:\/\/dx.doi.org\/10.1002\/jmv.29082
\n6 Gentry CA, Nguyen P, Thind SK, Kurdgelashvili G,
\nWilliams RJ. Characteristics and outcomes of US Veterans
\nat least 65 years of age at high risk of severe SARS-CoV-2
\ninfection with or without receipt of oral antiviral agents. J
\nInfect [Internet]. 2023;86(3):248\u201355. Available from:
\nhttp:\/\/dx.doi.org\/10.1016\/j.jinf.2023.01.018
\n7 Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao
\nW, Wisemandle W, et al. Oral nirmatrelvir for high-risk,
\nnonhospitalized adults with covid-19. N Engl J Med
\n[Internet]. 2022;386(15):1397\u2013408. Available from:
\nhttp:\/\/dx.doi.org\/10.1056\/nejmoa2118542
\n8 Kaizer AM, Shapiro NI, Wild J, Brown SM, Cwik BJ, Hart
\nKW, et al. Lopinavir\/ritonavir for treatment of nonhospitalized patients with COVID-19: a randomized
\nclinical trial. Int J Infect Dis [Internet]. 2023;128:223\u20139.
\nAvailable from:
\nhttp:\/\/dx.doi.org\/10.1016\/j.ijid.2022.12.028
\n9 Keitel V, RES-Q-HR Trial Team, Jensen B, Feldt T, Fischer
\nJC, Bode JG, et al. Reconvalescent plasma\/camostat
\nmesylate in early SARS-CoV-2 Q-PCR positive high-risk
\nindividuals (RES-Q-HR): a structured summary of a study
\nprotocol for a randomized controlled trial. Trials
\n[Internet]. 2021;22(1). Available from:
\nhttp:\/\/dx.doi.org\/10.1186\/s13063-021-05181-0
\n10 Lakatos B, Kowalska J, Antoniak S, Gokengin D,
\nBegovac J, Vassilenko A, et al. Retrospective evaluation of
\nan observational cohort by the Central and Eastern
\nEurope Network Group shows a high frequency of
\npotential drug\u2013drug interactions among HIV\u2011positive
\npatients receiving treatment for coronavirus disease 2019
\n(COVID\u201119). HIV Med [Internet]. 2022;23(6):693\u2013700.
\nAvailable from: http:\/\/dx.doi.org\/10.1111\/hiv.13214
\n11 McCarthy MW. VV116 as a potential treatment for
\nCOVID-19. Expert Opin Pharmacother [Internet]. 2023
\n[cited 2023 Nov 9];675\u20138. Available from:
\nhttps:\/\/pesquisa.bvsalud.org\/global-literature-on-novelcoronavirus-2019-ncov\/resource\/ru\/covidwho-2271505
\n12 McEvoy NL, Clarke JL, Mc Elvaney OJ, Mc Elvaney OF,
\nBoland F, Hyland D, et al. A randomised, double-blind,
\nplacebo-controlled, pilot trial of intravenous plasma
\npurified alpha-1 antitrypsin for SARS-CoV-2-induced
\nAcute Respiratory Distress Syndrome: a structured
\nsummary of a study protocol for a randomised, controlled
\ntrial. Trials [Internet]. 2021;22(1):288. Available from:
\nhttp:\/\/dx.doi.org\/10.1186\/s13063-021-05254-0
\n13 Olagunju A, Fowotade A, Olagunoye A, Ojo TO, Adefuye
\nBO, Fagbamigbe AF, et al. Efficacy and safety of
\nnitazoxanide plus atazanavir\/ritonavir for the treatment
\nof moderate to severe COVID-19 (NACOVID): A structured
\nsummary of a study protocol for a randomised controlled
\ntrial. Trials [Internet]. 2021;22(1). Available from:
\nhttp:\/\/dx.doi.org\/10.1186\/s13063-020-04987-8
\n14 Palanques-Pastor T, Meg\u00edas-Vericat JE, Mart\u00ednez P,
\nL\u00f3pez Lorenzo JL, Cornago Navascu\u00e9s J, Rodriguez Macias
\nG, et al. Characteristics, clinical outcomes, and risk factors
\nof SARS-COV-2 infection in adult acute myeloid leukemia
\npatients: experience of the PETHEMA group. Leuk
\nLymphoma [Internet]. 2021;62(12):2928\u201338. Available
\nfrom:
\nhttp:\/\/dx.doi.org\/10.1080\/10428194.2021.1948031
\n15 Panda PK, Bandyopadhyay A, Singh BC, Moirangthem
\nB, Chikara G, Saha S, et al. Safety and efficacy of antiviral
\ncombination therapy in symptomatic patients of Covid-19
\ninfection – a randomised controlled trial (SEV-COVID
\nTrial): A structured summary of a study protocol for a
\nrandomized controlled trial. Trials [Internet]. 2020;21(1).
\nAvailable from: http:\/\/dx.doi.org\/10.1186\/s13063-020-
\n04774-5
\n16 Quinn TM, Gaughan EE, Bruce A, Antonelli J, O\u2019Connor
\nR, Li F, et al. Randomised controlled trial of intravenous
\nnafamostat mesylate in COVID pneumonitis: Phase 1b\/2a
\nexperimental study to investigate safety,
\nPharmacokinetics and Pharmacodynamics. EBioMedicine
\n[Internet]. 2022;76(103856):103856. Available from:
\nhttp:\/\/dx.doi.org\/10.1016\/j.ebiom.2022.103856
\n17 Santos CS, Morales CM, \u00c1lvarez ED, Castro C\u00c1, Robles
\nAL, Sandoval TP. Determinants of COVID-19 disease
\nseverity in patients with underlying rheumatic disease.
\nClin Rheumatol [Internet]. 2020;39(9):2789\u201396. Available
\nfrom: http:\/\/dx.doi.org\/10.1007\/s10067-020-05301-2
\n18 Singh RSP, Toussi SS, Hackman F, Chan PL, Rao R, Allen
\nR, et al. Innovative randomized phase I study and dosing
\n144
\nregimen selection to accelerate and inform pivotal
\nCOVID\u201119 trial of nirmatrelvir. Clin Pharmacol Ther
\n[Internet]. 2022;112(1):101\u201311. Available from:
\nhttp:\/\/dx.doi.org\/10.1002\/cpt.2603
\n19 Vicenzi M, Di Cosola R, Ruscica M, Ratti A, Rota I, Rota
\nF, et al. The liaison between respiratory failure and high
\nblood pressure: evidence from COVID-19 patients. Eur
\nRespir J [Internet]. 2020;56(1):2001157. Available from:
\nhttp:\/\/dx.doi.org\/10.1183\/13993003.01157-2020
\n20 WHO supports scientifically-proven traditional
\nmedicine [Internet]. WHO | Regional Office for Africa.
\n[cited 2023 Nov 9]. Available from:
\nhttps:\/\/www.afro.who.int\/news\/who-supportsscientifically-proven-traditionalmedicine?gclid=Cj0KCQiAo7KqBhDhARIsAKhZ4ugZu0jM
\nUwYlndZXcXmh7HTb_2l2LsB1qr18r8Jp6pVm27wFvddjRUaApkKEALw_wcB
\n21 Xu Z, Shi D, Han J-B, Ling Y, Jiang X, Lu X, et al.
\nPreventive and therapeutic benefits of nelfinavir in
\nrhesus macaques and human beings infected with SARSCoV-2. Signal Transduct Target Ther [Internet].
\n2023;8(1). Available from:
\nhttp:\/\/dx.doi.org\/10.1038\/s41392-023-01429-0
\n22 Robinson P, Toussi SS, Aggarwal S, Bergman A, Zhu T,
\nHackman F, et al. Safety, tolerability, and
\npharmacokinetics of single and multiple ascending
\nintravenous infusions of PF-07304814 (lufotrelvir) in
\nparticipants hospitalized with COVID-19. Open Forum
\nInfect Dis [Internet]. 2023;10(8). Available from:
\nhttp:\/\/dx.doi.org\/10.1093\/ofid\/ofad355
\n23 M\u00f3ty\u00e1n JA, Mahdi M, Hoffka G, T\u0151zs\u00e9r J. Potential
\nresistance of SARS-CoV-2 main protease (Mpro) against
\nprotease inhibitors: Lessons learned from HIV-1 protease.
\nInt J Mol Sci [Internet]. 2022;23(7):3507. Available from:
\nhttp:\/\/dx.doi.org\/10.3390\/ijms23073507
\n24 King NM, Prabu-Jeyabalan M, Nalivaika EA,
\nSchiffer CA. Combating susceptibility to drug resistance.
\nChem Biol [Internet]. 2004;11(10):1333\u20138. Available
\nfrom: http:\/\/dx.doi.org\/10.1016\/j.chembiol.2004.08.010
\n25 Da Cunha T, Wu GY, Vaziri H. Immunotherapyinduced hepatotoxicity: A review. J Clin Transl Hepatol
\n[Internet]. 2022;000(000):000\u2013000. Available from:
\nhttp:\/\/dx.doi.org\/10.14218\/jcth.2022.00105
\n26 Cho YA, Han JM, Kang SY, Kim DC, Youn YJ, Choi
\nKH, et al. Analysis of risk factors for hepatotoxicity
\ninduced by immune checkpoint inhibitors. J Immunother
\n[Internet]. 2021;44(1):16\u201321. Available from:
\nhttp:\/\/dx.doi.org\/10.1097\/cji.0000000000000347<\/p>\n

\r\n\t\"\"\r\n\r\n\t
\r\n\t\t\u0421\u043a\u0430\u0447\u0430\u0442\u044c: LITERATURE REVIEW: PROTEASE INHIBITORS AS PROMISING AGENTS IN THE FIGHT AGAINST COVID-19 \u2013 EVALUATION OF ANTIVIRAL ACTIVITY<\/a>\r\n\t\t
<\/div>\r\n\t\t
\u0421\u043a\u0430\u0447\u0430\u043d\u043e: 174, \u0440\u0430\u0437\u043c\u0435\u0440: 1.0 MB<\/div>\r\n\t<\/div>\r\n\t\r\n<\/div>\r\n\r\n